背靠商业航天高景气赛道，陕西华达科技股份有限公司（以下简称"陕西华达"，301517.SZ）在2026年 开年迎来经营与资本运作的双重考验。 日前，陕西华达发布公告，正式宣布终止通过发行股份方式购买陕西华经微电子股份有限公司（以下简 称"华经微电子"）100%股权并募集配套资金的事项。 这意味着，筹划半年之久的产业链整合计划最终 折戟。与此同时，陕西华达披露的2025年度业绩预告显示，公司预计2025年全年归属于上市公司股东的 净利润为亏损5900万元至7900万元，同比由盈转亏，扣非后净利润亏损6500万元至8500万元。 一边是核心业务盈利承压，一边是外延扩张遇阻，身处军工电子与商业航天双风口的陕西华达，为何陷 入业绩与资本运作的双重困局？重组终止后，公司既定的战略布局将如何推进？ 中经记者 王登海 西安报道 业绩变脸 作为国内最早从事电连接器研发生产的企业之一，陕西华达主营业务为电连接器及互连产品的研发、生 产和销售，核心产品涵盖射频同轴连接器、低频连接器、射频同轴电缆组件等，广泛应用于航空航天、 武器装备、通信等国家战略性领域，是当前商业航天、军工电子等高景气赛道的核心配套商。 2023年10月，陕西 ...

Group 1: Company Overview and Market Position - The company is a significant manufacturer of electrical connectors in the aerospace sector, with a strong project history and technical expertise [3] - It actively participates in national aerospace projects, focusing on low-cost solutions and enhancing industrial capabilities [3] - The company aims to expand its product offerings in commercial aerospace, including RF connectors, high-speed connectors, and optical components, to increase the value per satellite [3] Group 2: Strategic Development and Innovation - The company has a long-term R&D investment strategy aimed at transitioning from a component supplier to a system solution provider [3] - It has achieved advancements in integration, high power, lightweight, and cost-effective solutions for its products [3] - Future R&D will focus on emerging fields such as commercial aerospace, low-altitude economy, and artificial intelligence [3] Group 3: Quantum Technology and Policy Compliance - The company is exploring quantum technology applications, having pre-researched RF transmission systems suitable for quantum computing [4] - It is committed to adhering to provincial policies that support high-quality development, aligning its capital market strategy with these regulations [4] - The company emphasizes transparent communication with investors and compliance with information disclosure regulations [4]

Investment Rating - The report maintains a "Recommended" rating for the company [4][6]. Core Views - The company reported a revenue of 250 million yuan in the first half of 2025, a year-over-year decline of 22.8%, with a net profit attributable to shareholders of -14 million yuan, compared to 25 million yuan in the first half of 2024. The performance aligns with expectations [1]. - In the second quarter of 2025, the company saw a significant quarter-on-quarter revenue increase of 95.4%, reaching 170 million yuan, with a year-over-year growth of 14.7%. However, the net profit decreased by 68.8% year-over-year, but turned positive from a loss in the first quarter [1]. - The company is one of the earliest manufacturers of electrical connectors in China, with over fifty years of experience, and has established a stable customer base. It is actively optimizing its industrial structure and expanding into new business areas such as quantum technology, semiconductors, and data centers [4]. Summary by Sections Financial Performance - The company's gross margin for the first half of 2025 decreased by 2.8 percentage points to 35.2%, while the net margin fell by 12.5 percentage points to -4.8%. In the second quarter, the gross margin was 33.1%, down 10.2 percentage points year-over-year, and the net margin was 4.1%, down 6.6 percentage points [1]. - The company experienced a significant increase in research and development expenses, with the R&D expense ratio rising by 3.1 percentage points to 10.0% and total R&D expenses increasing by 12.2% to 25 million yuan [3]. Product Performance - In the first half of 2025, the revenue breakdown by product showed that the RF coaxial connectors generated 110 million yuan (44% of total revenue, down 20.6% year-over-year), low-frequency connectors 60 million yuan (23%, down 25.2%), RF coaxial cable assemblies 50 million yuan (19%, down 33.0%), and electroplating services 10 million yuan (3%, up 90.3%) [2]. Future Outlook - The company is expected to achieve net profits of 67 million yuan, 151 million yuan, and 223 million yuan for the years 2025, 2026, and 2027, respectively. The current stock price corresponds to price-to-earnings ratios of 117x, 52x, and 35x for the same years [4][5].

Group 1: New IPOs - Three new stocks are set to be offered for subscription this week: Knight Dairy, Runben Co., and Shaanxi Huada [1][2] - Knight Dairy focuses on the dairy and sugar industries, operating as a comprehensive supplier of dairy products across the entire industry chain [2] - Runben Co. specializes in mosquito repellent and personal care products, recognized as a leading domestic brand in the mosquito repellent sector [1][3] - Shaanxi Huada is one of the earliest manufacturers of electrical connectors in China, currently controlled by the Shaanxi Provincial State-owned Assets Supervision and Administration Commission [1] Group 2: Knight Dairy - Knight Dairy's main business includes the cultivation of forage, corn, and sugar beets, intensive dairy farming, and the production and sale of dairy products and white sugar [2] - The company has achieved revenues of 707 million yuan, 876 million yuan, and 948 million yuan from 2020 to 2022, with net profits of 22.88 million yuan, 55.73 million yuan, and 71.62 million yuan respectively [2] Group 3: Runben Co. - Runben Co. has developed three core product lines: mosquito repellent, baby care products, and essential oils, with a strong online sales presence [3] - The online sales channel contributed 78.73%, 77.72%, and 78.04% to the company's revenue from 2020 to 2022 [3] - The "Runben" brand ranked first in market share for mosquito repellent liquid on Tmall, with sales proportions of 16.42%, 18.32%, and 19.99% over the same period [3] - The company reported revenues of 443 million yuan, 582 million yuan, and 856 million yuan from 2020 to 2022, with net profits of 95 million yuan, 121 million yuan, and 160 million yuan respectively [3] Group 4: Shaanxi Huada - Shaanxi Huada specializes in the research, production, and sales of electrical connectors and interconnect products, with applications in aerospace, military equipment, and communications [4] - The company has produced high-reliability connectors used in key national aerospace projects, including the Chang'e lunar exploration series and the Tianwen Mars exploration system [4] - From 2020 to 2022, the company achieved revenues of 637 million yuan, 756 million yuan, and 802 million yuan, with net profits of 57.62 million yuan, 66.74 million yuan, and 64.57 million yuan respectively [4]

Group 1 - The core viewpoint of the report is that Shaanxi Huada is experiencing significant revenue and profit declines in 2024 and Q1 2025, but there are signs of recovery in defense demand and promising prospects in commercial aerospace [1][2][3] Group 2 - In 2024, the company achieved operating revenue of 630 million yuan, a year-on-year decrease of 26%, and a net profit attributable to shareholders of 47 million yuan, down 41% year-on-year [2] - In Q1 2025, the company reported operating revenue of 86 million yuan, a 53% year-on-year decline, and a net profit attributable to shareholders of -18 million yuan, a decrease of 283% year-on-year [2] Group 3 - The decline in revenue and profit is primarily due to a challenging market environment, including the suspension of some military projects and a decrease in military orders [2] - The company is implementing measures to enhance order fulfillment capabilities, including optimizing order scheduling and increasing automation levels, which may lead to a turning point in performance [2][3] Group 4 - The company is strategically positioned in the aerospace, weaponry, and communications sectors, with a focus on key national projects, indicating a broad potential in the commercial aerospace market [3] - Projected net profits for 2025, 2026, and 2027 are expected to be 81 million yuan, 123 million yuan, and 166 million yuan, representing year-on-year growth rates of 74%, 52%, and 35% respectively [3]

Group 1: Broker Research Focus - Since May, brokers have conducted research on over 670 listed companies, with high attention on sectors such as electronics, pharmaceuticals, and non-ferrous metals [1][4] - The electronics sector has been the most frequently researched, with over 90 companies being targeted, including Anji Technology and Huanxun Technology, which received attention from at least 25 brokers [3] - The pharmaceutical sector has also seen significant interest, with nearly 60 companies being researched, including Huadong Medicine and Sanyou Medical, with over 15 brokers involved in their investigations [4] Group 2: Military Industry Interest - The defense and military sector has experienced a surge in research interest, with over 20 companies being investigated since May, including Aerospace Nanhu and Xi'an Huada [6] - Aerospace Nanhu has reported a stock price increase of over 102% this year and has a backlog of orders worth 1.4 billion yuan [6][7] - Xi'an Huada has noted a positive recovery in defense sector demand since March, following a slow start to the year [6] Group 3: Stock Rating Adjustments - Since May, nearly 50 stocks have had their ratings adjusted, with 17 stocks being upgraded, including Sifang Co. and Weicai Technology [2][8] - For example, Tianfeng Securities upgraded Sifang Co. from "Hold" to "Buy" due to stable business development [9] - Conversely, over 30 stocks have seen their ratings downgraded, including Wentai Technology, which was downgraded from "Buy" to "Hold" due to changes in its main business structure [9]

Core Viewpoint - The article highlights the increasing focus of brokerage firms on various sectors, particularly electronics, pharmaceuticals, non-ferrous metals, and defense industries, with significant changes in stock ratings and research activities since May. Group 1: Brokerage Research Focus - Brokerage firms have conducted research on over 670 listed companies since May, with high attention on sectors like electronics, pharmaceuticals, and non-ferrous metals, as well as a notable rise in interest in the defense industry [1][5][7]. - The electronics sector has seen over 90 companies researched, with firms like Anji Technology and Huanxun Technology receiving attention from more than 25 brokerages [4][5]. - The pharmaceutical sector has also gained traction, with nearly 60 companies being researched, including Huadong Medicine and Sunlight Nuohe, which are focusing on innovative drug pipelines [5][6]. Group 2: Stock Rating Adjustments - Since May, nearly 50 stocks have had their ratings changed, with 17 stocks being upgraded, such as Sifang Co. and Weicai Technology, indicating a positive outlook on their business developments [2][10]. - Conversely, over 30 stocks have seen downgrades, including Wentai Technology and Tongwei Co., due to concerns over profitability and market conditions affecting their respective sectors [2][11]. - The adjustments in ratings reflect a dynamic response to market conditions and company performance, with analysts actively reassessing their forecasts [10][11].